BRPI0306559B8 - pharmaceutical composition for oral application for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-acid ethylester mesylate 2-yl-amino]-propionic and its preparation process - Google Patents

pharmaceutical composition for oral application for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-acid ethylester mesylate 2-yl-amino]-propionic and its preparation process

Info

Publication number
BRPI0306559B8
BRPI0306559B8 BRPI0306559A BR0306559A BRPI0306559B8 BR PI0306559 B8 BRPI0306559 B8 BR PI0306559B8 BR PI0306559 A BRPI0306559 A BR PI0306559A BR 0306559 A BR0306559 A BR 0306559A BR PI0306559 B8 BRPI0306559 B8 BR PI0306559B8
Authority
BR
Brazil
Prior art keywords
methyl
hexyloxycarbonylamino
benzimidazol
phenylamino
imino
Prior art date
Application number
BRPI0306559A
Other languages
Portuguese (pt)
Other versions
BR0306559A (en
BRPI0306559B1 (en
Inventor
Hauel Norbert
Sieger Peter
Brauns Ulrich
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27789735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0306559(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10209985A external-priority patent/DE10209985A1/en
Priority claimed from DE2002145624 external-priority patent/DE10245624A1/en
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Int
Publication of BR0306559A publication Critical patent/BR0306559A/en
Publication of BRPI0306559B1 publication Critical patent/BRPI0306559B1/en
Publication of BRPI0306559B8 publication Critical patent/BRPI0306559B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"forma de aplicação oral para etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil)-1-metil-1h-benzimidazol-5-carbonil)-piridin2-il-amino]-propiônico e seus sais". a presente invenção refere-se a uma nova forma de aplicação oral a ser aplicada para a substância ativa etiléster de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]meti]}-1 -metil-1h-benzimidazol-5-carbonil)-piridin-2-il-amino]-propiônico e seus sais farmaceuticamente compatíveis."oral application form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl)-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin2-yl-acid ethylesters amino]-propionic and its salts". the present invention relates to a new oral application form to be applied for the active substance 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl]}-1-methyl acid ethylester -1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic and its pharmaceutically compatible salts.

BRPI0306559A 2002-03-07 2003-03-03 pharmaceutical composition for oral application for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-acid ethylester mesylate 2-yl-amino]-propionic and its preparation process BRPI0306559B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (en) 2002-03-07 2002-03-07 Oral pharmaceutical composition comprises the thrombin inhibitor ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate and an organic acid
DE10209985.5 2002-03-07
DE10245624.0 2002-09-30
DE2002145624 DE10245624A1 (en) 2002-09-30 2002-09-30 Oral pharmaceutical composition comprises the thrombin inhibitor ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate and an organic acid
PCT/EP2003/002141 WO2003074056A1 (en) 2002-03-07 2003-03-03 Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally

Publications (3)

Publication Number Publication Date
BR0306559A BR0306559A (en) 2004-11-30
BRPI0306559B1 BRPI0306559B1 (en) 2021-05-18
BRPI0306559B8 true BRPI0306559B8 (en) 2021-05-25

Family

ID=27789735

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0306559A BRPI0306559B8 (en) 2002-03-07 2003-03-03 pharmaceutical composition for oral application for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-acid ethylester mesylate 2-yl-amino]-propionic and its preparation process

Country Status (36)

Country Link
US (2) US20190231766A1 (en)
EP (2) EP1485094B2 (en)
JP (3) JP3866715B2 (en)
KR (1) KR101005716B1 (en)
CN (1) CN100528157C (en)
AR (2) AR042861A1 (en)
AT (1) ATE540943T1 (en)
AU (1) AU2003210400B8 (en)
BR (1) BRPI0306559B8 (en)
CA (1) CA2476054C (en)
CL (1) CL2009001915A1 (en)
CO (1) CO5611149A2 (en)
CY (4) CY1112796T1 (en)
DE (1) DE122012000047I1 (en)
DK (2) DK1485094T4 (en)
EA (1) EA009664B1 (en)
EC (1) ECSP045331A (en)
ES (2) ES2380704T3 (en)
HK (1) HK1078792A1 (en)
HR (1) HRP20040807B1 (en)
IL (3) IL163863A0 (en)
LU (2) LU92025I2 (en)
ME (1) ME00325B (en)
MX (1) MXPA04008542A (en)
MY (1) MY143734A (en)
NO (3) NO326918B1 (en)
NZ (2) NZ546367A (en)
PE (1) PE20030889A1 (en)
PL (2) PL212566B1 (en)
PT (2) PT1870100E (en)
RS (1) RS52088B (en)
SG (1) SG146435A1 (en)
SI (2) SI1485094T2 (en)
TW (1) TWI293879B (en)
WO (1) WO2003074056A1 (en)
ZA (1) ZA200406071B (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (en) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
DE10339862A1 (en) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis
DE10341043A1 (en) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg New Oral Dosage Form for 3 - [(2 - {[4-hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] Propionic acid ethyl ester and its salts
WO2005113010A1 (en) * 2004-05-24 2005-12-01 Qualicaps Co., Ltd. Surface-modified and solubility-improved hard capsule
DE102004062864A1 (en) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg foil container
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005025728A1 (en) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester
DE102005061623A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts
DE102005061624A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines
CL2007002067A1 (en) * 2006-07-17 2008-01-25 Boehringer Ingelheim Int Use of dabigatran etexilate, direct thrombin inhibitors, for the treatment and / or prophylaxis in children of diseases such as non-hemorrhagic cerebral infarction, myocardial infarction, arrhythmia, central venous thrombosis, among others.
KR20090029849A (en) * 2006-07-17 2009-03-23 베링거 인겔하임 인터내셔날 게엠베하 New indications for direct thrombin inhibitors in the cardiovascular field
EP2074112A1 (en) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
JP2011515438A (en) * 2008-03-28 2011-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method of producing acid pellet
MX2010010647A (en) * 2008-03-28 2010-10-20 Boehringer Ingelheim Int Process for preparing orally administered dabigatran formulations.
JP2011527318A (en) * 2008-07-14 2011-10-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for producing pharmaceutical composition containing dabigatran
TW201431552A (en) 2008-07-28 2014-08-16 Takeda Pharmaceutical Pharmaceutical composition
WO2010020602A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Dabigatran for percutaneous interventional cardiac catheterisation
EP2328581A1 (en) * 2008-08-19 2011-06-08 Boehringer Ingelheim International GmbH Use of dabigatranetexilate for treating patients with pulmonary hypertension
JP2012526766A (en) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング A novel combination therapy in the treatment of neoplastic and fibrotic diseases
ES2436076T3 (en) 2009-08-24 2013-12-26 Boehringer Ingelheim International Gmbh Emergency interventions of active charcoal with overdosing with dabigatran etexilate
WO2011107427A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
US20130149346A1 (en) 2010-03-08 2013-06-13 ratiopharm GmbH Graf-Arco-Strasse 3 Dabigatran etexilate-containing pharmaceutical composition
EP2588090B2 (en) 2010-07-01 2023-11-22 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
US20130116441A1 (en) 2010-07-09 2013-05-09 Esteve Quimica, S.A. Intermediates and process for preparing a thrombin specific inhibitor
JP2013532164A (en) 2010-07-09 2013-08-15 エステヴェ キミカ， エス．エー． Methods for preparing thrombin specific inhibitors
PL2603503T3 (en) 2010-09-27 2015-12-31 Ratiopharm Gmbh Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
EA201391758A1 (en) * 2011-05-24 2014-06-30 Тева Фармасьютикал Индастриз Лтд. SPRONGED HEART FOR PHARMACEUTICAL COMPOSITION CONTAINING ORGANIC ACIDS
CN102391250B (en) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 Dabigatran compound and preparation method and medicinal composition thereof
MX2014007331A (en) * 2011-12-22 2014-09-01 Boehringer Ingelheim Int Immediate release multi unit pellet system.
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
WO2013110567A1 (en) 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
RS62566B1 (en) * 2012-02-21 2021-12-31 Towa Pharmaceutical Europe S L Oral pharmaceutical compositions of dabigatran etexilate
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
WO2013150545A2 (en) 2012-04-02 2013-10-10 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
US20150225370A1 (en) 2012-09-28 2015-08-13 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
US20150246899A1 (en) 2012-09-28 2015-09-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014060561A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
WO2014060545A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of dabigatran free base
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (en) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 Pharmaceutical composition containing dabigatran etexilate or salt and hydrate thereof
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104414995A (en) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 Pharmaceutical composition of dabigatran etexilate mesylate
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
IN2014MU01042A (en) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155297A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
DE102014108210A1 (en) 2014-06-11 2015-12-17 Dietrich Gulba rodenticide
CA3001495C (en) 2014-11-03 2021-07-20 Solipharma Llc Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof
CN105640909B (en) 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 A kind of Pharmaceutical composition containing dabigatran etcxilate
JP6581197B2 (en) * 2014-12-31 2019-09-25 深▲セン▼市薬欣生物科技有限公司Ｓｈｅｎｚｈｅｎ Ｐｈａｒｍａｃｉｎ Ｃｏ．， Ｌｔｄ． Pharmaceutical composition and method for producing the same
CN106924256B (en) * 2015-12-25 2022-08-19 深圳市药欣生物科技有限公司 Pharmaceutical composition and preparation method thereof
CN105797162B (en) * 2014-12-31 2022-10-25 昆明积大制药股份有限公司 Surface modification method for pharmaceutic adjuvant
TR201502223A2 (en) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dronedarone and dabigatran
WO2016161576A1 (en) * 2015-04-08 2016-10-13 杭州领业医药科技有限公司 Pellet containing cysteine hydrochloride and preparation method thereof
MA42480A (en) 2015-07-20 2018-05-30 Sanovel Ilac Sanayi Ve Ticaret As DABIGATRAN PHARMACEUTICAL PREPARATIONS IN FREE BASE FORM
CN105919962B (en) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 A kind of dabigatran etcxilate tablet and preparation method thereof
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TR201606697A2 (en) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi NEW ORAL PHARMACEUTICAL FORMULATIONS OF DABIGATRA
WO2018104387A1 (en) 2016-12-07 2018-06-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayered tablet compositions of dabigatran
TR201617984A2 (en) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN
WO2018122262A1 (en) 2016-12-28 2018-07-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Bilayer tablet formulations of dabigatran etexilate
JP2018184375A (en) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tablet comprising dabigatran etexilate or pharmaceutically acceptable salt thereof and method for producing the same
WO2018229784A1 (en) * 2017-06-14 2018-12-20 Natco Pharma Limited Pharmaceutical compositions of dabigatran
CN109125274A (en) * 2017-06-28 2019-01-04 上海美悦生物科技发展有限公司 Medicinal acid composition of injection benzimidazole and its preparation method and application
TR201722323A2 (en) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral pharmaceutical compositions of dabigatran
TR201722353A2 (en) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL FORMULATION FOR ORAL APPLICATION WITH DABIGATRAN SKIRT
TR201722186A2 (en) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of dabigatran
TR201722630A2 (en) * 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (en) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 Pharmaceutical composition containing dabigatran etexilate and preparation method thereof
KR20200082641A (en) 2018-12-31 2020-07-08 주식회사 유영제약 Pharmaceutical composition comprising dabigatran etexilate
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
KR20210157691A (en) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 Pharmaceutical Composition For Oral Administration Comprising Dabigtran Etextilate
KR20210157692A (en) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 Pharmaceutical Composition For Oral Administration Comprising Dabigtran Etextilate
KR20210157693A (en) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 Pharmaceutical Composition For Oral Administration Comprising Dabigtran Etextilate
CN114306245A (en) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 Pharmaceutical composition of amorphous solid dispersion and preparation method thereof
EP4070658A1 (en) 2021-04-06 2022-10-12 BIORoxx GmbH Use of anticoagulant active compounds as rodenticide
CN115227663B (en) * 2021-04-22 2023-12-12 石药集团恩必普药业有限公司 Dabigatran etexilate mesylate capsule and preparation method thereof
WO2023139243A1 (en) 2022-01-21 2023-07-27 Adamed Pharma S.A A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
GR1010399B (en) * 2022-04-05 2023-02-03 Φαρματεν Α.Β.Ε.Ε., Pharmaceutical composition comprising an anticoagulant agent and method foa the preparation for the preperation thereof
WO2024175037A1 (en) * 2023-02-21 2024-08-29 广州玻思韬控释药业有限公司 Pellet of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2024217830A1 (en) 2023-03-30 2024-10-24 Adamed Pharma S.A A process for preparation of hard capsules filled with dabigatran pellets

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3126703A1 (en) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach BROMHEXIN RETARD FORM AND METHOD FOR THEIR PRODUCTION
JPS58134033A (en) * 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd Drug composition
PE121699A1 (en) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
DE10133786A1 (en) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Use of thrombin inhibitors for the treatment of arthritis

Also Published As

Publication number Publication date
KR20040099298A (en) 2004-11-26
US20200085807A1 (en) 2020-03-19
EP1485094B1 (en) 2012-07-04
PL210862B1 (en) 2012-03-30
IL209368A0 (en) 2011-01-31
EA200401136A1 (en) 2005-04-28
HRP20040807B1 (en) 2014-11-21
EP1485094A1 (en) 2004-12-15
ES2390661T3 (en) 2012-11-15
CN1638771A (en) 2005-07-13
CN100528157C (en) 2009-08-19
CY2012031I1 (en) 2015-08-05
ES2380704T9 (en) 2013-07-24
NO20081304L (en) 2004-06-07
CA2476054C (en) 2011-11-08
BR0306559A (en) 2004-11-30
RS52088B (en) 2012-06-30
SI1485094T1 (en) 2012-10-30
MY143734A (en) 2011-07-15
DK1485094T4 (en) 2020-06-22
ECSP045331A (en) 2006-04-19
LU92025I2 (en) 2012-08-20
IL163863A (en) 2013-02-28
NO20042361L (en) 2004-06-07
HK1078792A1 (en) 2006-03-24
MXPA04008542A (en) 2004-12-06
CL2009001915A1 (en) 2010-02-12
DE122012000047I1 (en) 2012-09-13
LU92117I2 (en) 2013-02-19
ATE540943T1 (en) 2012-01-15
BRPI0306559B1 (en) 2021-05-18
AR072385A2 (en) 2010-08-25
WO2003074056A1 (en) 2003-09-12
DK1485094T3 (en) 2012-10-15
IL163863A0 (en) 2005-12-18
AU2003210400B8 (en) 2008-09-25
PL394601A1 (en) 2011-07-18
CY2012020I2 (en) 2015-08-05
PL212566B1 (en) 2012-10-31
HRP20040807A2 (en) 2005-02-28
TWI293879B (en) 2008-03-01
PE20030889A1 (en) 2003-12-10
JP2005519099A (en) 2005-06-30
AU2003210400B2 (en) 2008-08-07
NZ546367A (en) 2008-08-29
TW200306188A (en) 2003-11-16
NO332209B1 (en) 2012-07-30
CA2476054A1 (en) 2003-09-12
CY1113158T1 (en) 2015-08-05
US20190231766A1 (en) 2019-08-01
PT1870100E (en) 2012-04-17
DK1870100T3 (en) 2012-05-14
JP2007056018A (en) 2007-03-08
RS79204A (en) 2007-02-05
SI1485094T2 (en) 2020-08-31
CO5611149A2 (en) 2006-02-28
PT1485094E (en) 2012-10-09
CY2012020I1 (en) 2015-08-05
EA009664B1 (en) 2008-02-28
JP3866715B2 (en) 2007-01-10
ES2380704T3 (en) 2012-05-17
CY2012031I2 (en) 2015-08-05
SI1870100T1 (en) 2012-05-31
IL209368A (en) 2012-10-31
ES2390661T5 (en) 2020-12-04
MEP50708A (en) 2011-02-10
EP1870100B1 (en) 2012-01-11
EP1485094B2 (en) 2020-03-25
NO2013001I2 (en) 2014-09-01
AR042861A1 (en) 2005-07-06
ZA200406071B (en) 2005-11-30
CY1112796T1 (en) 2015-08-05
NO326918B1 (en) 2009-03-16
NO20042361D0 (en) 2004-06-07
JP4953727B2 (en) 2012-06-13
NZ535663A (en) 2006-06-30
SG146435A1 (en) 2008-10-30
PL370517A1 (en) 2005-05-30
ME00325B (en) 2011-05-10
AU2003210400A1 (en) 2003-09-16
KR101005716B1 (en) 2011-01-05
JP2006328081A (en) 2006-12-07
EP1870100A1 (en) 2007-12-26
NO2013001I1 (en) 2013-02-11

Similar Documents

Publication Publication Date Title
BRPI0306559B8 (en) pharmaceutical composition for oral application for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-acid ethylester mesylate 2-yl-amino]-propionic and its preparation process
MY145696A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-menthyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament
BR0108870A (en) Hydrochloride salts of 5- [4- [2- (n-methyl-n- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione
BR0315574A (en) Amorphous form of esomeprazole, pharmaceutical composition containing it and process for its preparation
HRP20010343B1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
JP2007016035A5 (en)
AR045317A1 (en) CRYSTAL FORM OF AGONISTA DL ADRENERGIC RECEIVER B2
RS54580B1 (en) New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
BR0214199A (en) Phenoxy amine compositions to release active agents, dosage unit form and method of administration
TW200640455A (en) Oral dosage form comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
NO20074199L (en) New pharmaceutical compositions useful in the treatment of Parkinson's disease
CY1106226T1 (en) 5-[4-[2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY]BENZYL]THIAZOLIDINO-2,4-DIONE MESYLATE SALT
MX2023012521A (en) Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino )-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroet hyl)pyrrolidine-1-carboxamide and salts thereof.
EA201000701A1 (en) 4- [4- (2-ADAMANTHYLKARBAMOIL) -5-TRET-BUTYL-Pyrazole-1-IL] BENZOIC ACID-465
MY148695A (en) Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]-piperidine
PE20050335A1 (en) ORAL DOSAGE FORM INCLUDING 5- [4- [2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETOXY] BENZYL] THIAZOLIDIN-2,4-DIONA AND PROCEDURE FOR THE PREPARATION
EA200300345A1 (en) HYDROCHLORIDE SALT 5- [4- [2- (N-METHYL-N- (2-Pyridyl) AMINO) ETOXY] BENZYL] THIAZOLIDIN-2,4-DIONA
UA95601C2 (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester-methanesulphonate and pharmaceutical composition comprising thereof
EA200300234A1 (en) TARTRAT SALTS DERIVATIVE TIAZOLIDINDIONA
ATE435006T1 (en) PHARMACEUTICAL PREPARATION FOR THE ORAL CAVITY
PT1446404E (en) EDISILATES OF ROSIGLITAZONE AND ITS USE AS ANTIDIABETICS
EA200300231A1 (en) TARTRAT SALTS DERIVATIVE TIAZOLIDINDIONA
BRPI0401888A (en) Oral application form for 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1h-benzimidazol-5-carbonyl) -pyridin-2-acid ethyl esters il-amino] -propionic and its salts
BR0112915A (en) Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione derivative
CY1107421T1 (en) THIAZOLIDINODIONI PRODUCER TRADITIONAL SALTS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/03/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 03/03/2023